Phaseline

Companies › Accent Therapeutics

Accent Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATX-295
KIF18A inhibitor
KIF18APhase 1Advanced Solid TumorsApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06799065ATX-295Phase 1Advanced Solid TumorsOncologyApr 2027

Targets

KIF18A (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.